<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363906</url>
  </required_header>
  <id_info>
    <org_study_id>16878</org_study_id>
    <secondary_id>H9X-MC-GBGM</secondary_id>
    <nct_id>NCT03363906</nct_id>
  </id_info>
  <brief_title>A Study of Dulaglutide in Healthy Participants</brief_title>
  <official_title>Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a new formulation of dulaglutide (study drug)
      administered under the skin as one injection using a single dose pen compared to three
      injections using a pre filled syringe.

      This study will evaluate how much of the study drug enters the body and how long it takes the
      body to get rid of it. Information about any side effects that may occur will also be
      collected.

      The study will last about 84 days, including screening and will require overnight stays in
      the clinical research unit (CRU).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Dulaglutide</measure>
    <time_frame>Predose through 15 days post dose</time_frame>
    <description>PK: AUC of Dulaglutide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Dulaglutide</measure>
    <time_frame>Predose through 15 days post dose</time_frame>
    <description>PK: Cmax of Dulaglutide</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dulaglutide (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide administered subcutaneously (SC) in 3 prefilled syringes in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide administered SC in 1 single dose pen in one of two study periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide (Reference)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide (Reference)</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide (Test)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide (Test)</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy as determined by medical history and physical examination at time of
             screening

          -  Have a body mass index of greater than or equal to (≥) 23 kilograms per meter squared
             (kg/m²) inclusive

        Exclusion Criteria:

          -  Have known allergies to dulaglutide, glucagon-like peptide-1 (GLP-1) related
             compounds, or any components of the formulation

          -  Have family history of medullary thyroid cancer (MTC) or a genetic condition that
             predisposes to MTC

          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or
             idiopathic acute pancreatitis) or gastrointestinal disorder (e.g., relevant esophageal
             reflux or gall bladder disease) or any gastrointestinal disease which impacts gastric
             emptying (e.g., gastric bypass surgery, pyloric stenosis, with the exception of
             appendectomy) or could be aggravated by GLP-1 analogs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

